Drug Profile
Research programme: CCR2 antagonists - Janssen Research and Development/Johnson & Johnson
Alternative Names: CCR2 antagonists - Johnson & Johnson/Janssen Research and Development; Chemokine receptor-2 antagonists - Johnson & Johnson; JNJ-27553292Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Janssen Research & Development; Johnson & Johnson
- Developer Johnson & Johnson
- Class Azetidines; Cyclohexanes
- Mechanism of Action CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic rhinitis; Asthma; Autoimmune disorders; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Allergic-rhinitis in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (PO)